What is pharmacogenomics?: MedlinePlus Genetics

Posted on by

Pharmacogenomics is the study of how genes affect a persons response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a persons genetic makeup.

Many drugs that are currently available are one size fits all, but they don't work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the bodys response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions. Conditions that affect a persons response to certain drugs include clopidogrel resistance, warfarin sensitivity, warfarin resistance, malignant hyperthermia, Stevens-Johnson syndrome/toxic epidermal necrolysis, and thiopurine S-methyltransferase deficiency.

The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.

Read the original here:
What is pharmacogenomics?: MedlinePlus Genetics

Pharmacogenomics Market: Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2020 2027 – KSU | The Sentinel…

Posted on by

DBMR has added a new report titled Pharmacogenomics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This Pharmacogenomics Market report emphasizes on the detailed understanding of the some decisive factors such as size, share, sales, forecast trends, supply, production, demands, industry and CAGR in order to provide a comprehensive outlook of the global market. The conventional data in the global market report is presented in a graphical form while highlighting the proposed statistics. It also comprises of vendors, suppliers and key players in the global market. The unique data presented in the report are evaluated with an instinctive and scientific way in order to get a better understanding of the global market.

This Pharmacogenomics Market research report analyzes top players in the key regions like North America, South America, Middle east and Africa, Asia and Pacific region. It delivers insight and expert analysis into key consumer trends and behavior in market place, In addition to an overview of the market data and key brands. It also provides all data with easily digestible information to guide every businessmans future innovation and move business ahead.

Global pharmacogenomics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenomics-market&pm

Competitive Landscape and Global Pharmacogenomics Market Share Analysis

Pharmacogenomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global pharmacogenomics market.

The major players covered in the global pharmacogenomics market are Abbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, OPKO Health, Inc, Teva Pharmaceutical Industries Ltd, Myriad Genetics, Inc., QIAGEN,OneOme, LLC, Illumina, Inc, Empire Genomics, LLC, and Dynamic DNA Laboratories among others.

The factors primarily driven the growth of pharmacogenomics market are high adoption of personalized therapy. In addition, high prevalence of life-threatening disorders globally and improvement in molecular techniques for developing pharmacogenomics-based therapeutics are some of the impacting factors for the growth of this market. Nevertheless, less trained expertise or technically skilled professionals and coupled with difficulties in terracing gene variation that significantly affects the drug response are the factors that hinder the growth of this market.

Pharmacogenomics is the study of how human genes affect the way bodies responds to the medications. It is emerging field which combines the pharmacology and genomics to develop highly effective and right or safe medicines tailored to the patients genetic makeup.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharmacogenomics-market&pm

Global Pharmacogenomics Market Scope and Market Size

Pharmacogenomics market is segmented on the basis of technology, application, end-users and distribution channel.

Table of Contents-Snapshot

Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenomics-market&pm

Pharmacogenomics Market Country Level Analysis

Pharmacogenomics market is analysed and market size information is provided by country, technology, application, end-users and distribution channel as referenced above.

The countries covered in the global pharmacogenomics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth throughout the forecasted period due to the presence of refined healthcare expenditure and increased patient awareness level as well as preference personalized medicines. Europe is considered a second largest growing regional segment owing to the growing geriatric population and rising prevalence of chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pharmacogenomics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

Visit link:
Pharmacogenomics Market: Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2020 2027 - KSU | The Sentinel...

Pharmacogenomics Market Research Study including Growth Factors, New Top Players, Competitive Analysis by regions from 2020 to 2027 – The Courier

Posted on by

Databridgemarketresearch.com Present Pharmacogenomics Market Industry Trends and Forecast to 2027 new report to its research database. This analysis offers an examination of a range of segments that are relied upon to witness the quickest development amid the estimate forecast frame. The company profiles of all the key players and brands that are dominating the Pharmacogenomics Market with moves like product launches, joint ventures, mergers and acquisitions which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. A complete discussion about numerous market related topics in this research report is sure to aid the client in studying the market on competitive landscape. This report also gives you an idea about consumers demands, preferences, and their altering likings about particular product.

Global pharmacogenomics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenomics-market&pm

Competitive Landscape and Global Pharmacogenomics Market Share Analysis

Pharmacogenomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global pharmacogenomics market.

The major players covered in the global pharmacogenomics market are Abbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, OPKO Health, Inc, Teva Pharmaceutical Industries Ltd, Myriad Genetics, Inc., QIAGEN,OneOme, LLC, Illumina, Inc, Empire Genomics, LLC, and Dynamic DNA Laboratories among others.

The factors primarily driven the growth of pharmacogenomics market are high adoption of personalized therapy. In addition, high prevalence of life-threatening disorders globally and improvement in molecular techniques for developing pharmacogenomics-based therapeutics are some of the impacting factors for the growth of this market. Nevertheless, less trained expertise or technically skilled professionals and coupled with difficulties in terracing gene variation that significantly affects the drug response are the factors that hinder the growth of this market.

Pharmacogenomics is the study of how human genes affect the way bodies responds to the medications. It is emerging field which combines the pharmacology and genomics to develop highly effective and right or safe medicines tailored to the patients genetic makeup.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharmacogenomics-market&pm

Global Pharmacogenomics Market Scope and Market Size

Pharmacogenomics market is segmented on the basis of technology, application, end-users and distribution channel.

Table of Contents-Snapshot

Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenomics-market&pm

Pharmacogenomics Market Country Level Analysis

Pharmacogenomics market is analysed and market size information is provided by country, technology, application, end-users and distribution channel as referenced above.

The countries covered in the global pharmacogenomics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth throughout the forecasted period due to the presence of refined healthcare expenditure and increased patient awareness level as well as preference personalized medicines. Europe is considered a second largest growing regional segment owing to the growing geriatric population and rising prevalence of chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pharmacogenomics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

Read the original here:
Pharmacogenomics Market Research Study including Growth Factors, New Top Players, Competitive Analysis by regions from 2020 to 2027 - The Courier

European Molecular Diagnostics Market 2021-2026: Infectious Disease Segment is Expected to Hold the Major Market Share – Yahoo Finance

Posted on by

DUBLIN, Dec. 30, 2021 /PRNewswire/ -- The "Europe Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The European molecular diagnostics market was valued at USD 3,435 million in 2020, and it is expected to reach USD 7,790 million in 2026, registering a CAGR of 8.57% during the forecast period.

The COVID-19 outbreak is expected to positively impact the European molecular diagnostics market, as it involves the testing of various biological samples.

This is expected to aid the diagnosis of infectious diseases, such as COVID-19, as testing remains a crucial step in controlling the COVID-19 pandemic. Molecule diagnostics technology, such as next-generation sequencing, PCR, microarrays, etc., is increasingly adopted in the region for testing for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2).

Factors, such as the increasing burden of various bacterial and viral epidemics in this region, coupled with increasing demand for point-of-care diagnostics and recent advancements in pharmacogenomics, are expected to propel market growth over the forecast period.

As per the report published in 2019, HIV outcomes: Beyond Viral Suppression, around 86,000 people in Germany were living with HIV, whereas around 20% of the diseased population were living in Berlin.

Additionally, according to the estimates of the British Heart Foundation, in 2018, around 7 million people were living with heart and circulatory diseases in the United Kingdom, and healthcare costs relating to the heart and circulatory diseases were estimated at GBP 9 billion each year.

Thus, the heavy burden of chronic disease is anticipated to increase the adoption of molecular diagnostics in the region.

Key Market Trends

The Infectious Disease Segment is Expected to Hold the Major Market Share

The infectious disease segment is anticipated to hold one of the major market shares over the forecast period. The segment is driven by the huge burden of infectious disease in the European region. For instance, sexually transmitted infections (STIs) represent an important public health problem in the United Kingdom.

Story continues

According to the Health Protection Report 2019, 447,694 new STI diagnoses were made at sexual health services (SHSs) in England. Among these, the most commonly diagnosed STIs were chlamydia (218,095; 49% of all new STI diagnoses), first episode genital warts (57,318; 13%), gonorrhoea (56,259; 13%), and genital herpes (33,867; 8%). Therefore, a rise in the prevalence of such infectious disorders is expected to fuel the market growth during the forecast period.

Moreover, players in the region are expanding their regional market position by adopting various strategies, such as mergers and acquisitions, while others are developing new test methods for the diagnosis and introducing new products to retain their market share.

For instance, in May 2021, Swiss pharmaceutical giant, Roche, entered into a definitive merger agreement with GenMark Diagnostics, under which Roche may acquire GenMark's molecular tests designed to screen patient samples for multiple infections simultaneously. Hence, considering all the factors mentioned above, the market is expected to witness growth over the forecast period.

Competitive Landscape

The European molecular diagnostics market is competitive due to the presence of almost all global players in the molecular diagnostics market. Many of these global players have their headquarters in European countries, which increases the accessibility of molecular diagnostics tests throughout Europe.

Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technologies are some of the key players present in the European molecular diagnostics market. Many of the key players also have their R&D centers in Europe, which makes the availability of various products easier in the region.

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/lowqxd

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

Cision

View original content:https://www.prnewswire.com/news-releases/european-molecular-diagnostics-market-2021-2026-infectious-disease-segment-is-expected-to-hold-the-major-market-share-301451832.html

SOURCE Research and Markets

Continue reading here:
European Molecular Diagnostics Market 2021-2026: Infectious Disease Segment is Expected to Hold the Major Market Share - Yahoo Finance

The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review – DocWire News

Posted on by

This article was originally published here

Pharmacogenomics. 2020 Oct 30. doi: 10.2217/pgs-2020-0066. Online ahead of print.

ABSTRACT

Background: Despite potential benefits, the practice of incorporating pharmacogenomics (PGx) results in clinical decisions has yet to diffuse widely. In this study, we conducted a review of recent discussions on data standards and interoperability with a focus on sharing PGx test results among health systems. Materials & methods: We conducted a literature search for PGx clinical decision support systems between 1 January 2012 and 31 January 2020. Thirty-two out of 727 articles were included for the final review. Results: Nine of the 32 articles mentioned data standards and only four of the 32 articles provided solutions for the lack of interoperability. Discussions: Although PGx interoperability is essential for widespread implementation, a lack of focus on standardized data creates a formidable challenge for health information exchange. Conclusion: Standardization of PGx data is essential to improve health information exchange and the sharing of PGx results between disparate systems. However, PGx data standards and interoperability are often not addressed in the system-level implementation.

PMID:33124487 | DOI:10.2217/pgs-2020-0066

Link:
The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review - DocWire News

Brain Imaging, Biomarkers and NeuroInformatics Market to Witness Exponential Growth by 2024 – PRnews Leader

Posted on by

Imaging is now becoming an increasing important tool in both clinical and research. A wide range of imaging techniques commercially available provides sensitivity to visualization of brain structure and function from the level of individual molecules to whole brain. Hence, brain imaging helps the researchers or the physicians to identify the area of brain which are affected by neurological disorders. Moreover, brain imaging also help in formulating new strategies for the treatment of brain disorders and similarly enable imaging of the brain structure or for the diagnosis of metabolic diseases. Imaging methods are non invasive which also allow researchers to identify neural networks involved in the cognitive pathway. Likewise, neuroinformatics is the branch of science which is related with the organization of neuroscience data by the application of analytical tools and computational models. Neuroinformatics comprises multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level. Similarly, biomarkers is defined as measurable indicator that are used for identification of particular disease. Biomarkers are used for identification of progress of disease, evaluation of most effective therapeutic regime for particular or drug target identification. Thus, in the field of neuroscience biomarker plays an essential role in identification of number of neurological disorders and abnormalities.

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3851

Factors such as increase in geriatric population, investment in R&D and improved understanding of the nature of neurologic diseases are driving the market growth globally. Since, aged population is more prone to brain disorders therefore; increase in geriatric population will likely increase the neurodiagnostics market worldwide. Additionally, as per the World Health Organization, by 2020 nearly 14.1% of the world population will suffer from neurologic disorders which would further lure manufacturers to venture into this market.

Request a Sample of Brain Imaging, Biomarkers and NeuroInformatics Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3851

The market for neurodiagnostics can be segmented on the basis of three primary market segments neuroimaging market, in vitro diagnostics market and neuroinformatics market. Neuroimaging segment can be categorized into computed tomography (CT), nuclear medicine imaging (PET, SPECT), magneto-encepahlography (EEG), electro-encephalography and other imaging software. In vitro diagnostics segments can be subdivided into protein biomarker assay, pattern recognition diagnostics, genetic testing and pharmacogenomics. Likewise, the market for neuroinformatics is subdivided into software used for diagnostics and storage namely IBM Blue Brain Project, Paul Allen Brain Atlas Project and other software. Brain imaging techniques allows the technicians to visualize how quickly drugs reach to the receptors and their action mechanism. Moreover, these techniques also allow visualization of changes in brain activity after long term usage of drug.

Request for Analysis of COVID19 Impact on Brain Imaging, Biomarkers and NeuroInformatics Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=3851

Geographically, the market for brain imaging, neuroinformatics and biomarkers can be segmented into four regions namely North America, Europe, Asia-Pacific and Rest of the World. Currently North America and Europe account for the largest share of the market. It has been estimated that approximately 100 million people are suffering from brain or nervous system disorders such as Alzheimers disease, schizophrenia, Parkinsons disease, sleep disorders and others. Likewise, according to the National Institute of Mental Health in the U.S. about 1 in 4 adults suffer from brain disorders every year, with almost 6% of the population suffer from serious disabilities. Thus, for the diagnosis of these disorders rapidly new tools are being developed for more patients centered and personalized treatment. In the near future Asia-Pacific region is expected to witness significant growth to meet the massive unmet need for early diagnosis and disease monitoring.

Pre-Book Brain Imaging, Biomarkers and NeuroInformatics Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=3851&ltype=S

Abbot Diagnostics, Brain Resource, Advanced Brain Monitoring, Electrical Geodesics, Johnson & Johnson, GE Healthcare, NeuroVigil, Bio-Rad, Philips Healthcare, Quest Diagnostics, Aspect Medical (Covidien), NeuroVista, Natus Medical, BrainScope, Zynex and others are some of the major players operating in brain imaging, neuroinformatics and biomarkers market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers or customers journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,90 Sate Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.com/

Read More Reports: https://www.prnewswire.com/news-releases/women-opting-for-late-motherhood-driving-demand-for-non-invasive-prenatal-testing-transparency-market-research-301005822.html

Follow this link:
Brain Imaging, Biomarkers and NeuroInformatics Market to Witness Exponential Growth by 2024 - PRnews Leader

Comprehensive Report on Sports and Fitness Genomics and Pharmacogenomics Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027…

Posted on by

Sports and Fitness Genomics and Pharmacogenomics Market research report is the new statistical data source added by A2Z Market Research.

Sports and Fitness Genomics and Pharmacogenomics Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Sports and Fitness Genomics and Pharmacogenomics Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=281709

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

GeneDx, Assurex Health, 23andMe, Teva Pharmaceutical Industries, Future Science Group, Myriad Genetics, Pathway Genomics, GeneTech.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Sports and Fitness Genomics and Pharmacogenomics market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Sports and Fitness Genomics and Pharmacogenomics markets trajectory between forecast periods.

Global Sports and Fitness Genomics and Pharmacogenomics Market Segmentation:

Market Segmentation: By Type

MicroarraySequencingPolymerase Chain ReactionOthers

Market Segmentation: By Application

OncologyCardiologyNeurological DisordersOthers

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=281709

Regions Covered in the Global Sports and Fitness Genomics and Pharmacogenomics Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Sports and Fitness Genomics and Pharmacogenomics Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Sports and Fitness Genomics and Pharmacogenomics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Sports and Fitness Genomics and Pharmacogenomics market.

Table of Contents

Global Sports and Fitness Genomics and Pharmacogenomics Market Research Report 2021 2027

Chapter 1 Sports and Fitness Genomics and Pharmacogenomics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Sports and Fitness Genomics and Pharmacogenomics Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=281709

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

https://murphyshockeylaw.net/

Link:
Comprehensive Report on Sports and Fitness Genomics and Pharmacogenomics Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027...

2bPrecise acquired from Allscripts by AccessDX – Healthcare IT News

Posted on by

AccessDX Holdings, which develops an array of lab diagnostics and decision support tools, announced this week that it has acquired 2bPrecise from Allscripts.

WHY IT MATTERS2bPrecise specializes in helping health systems advance precision medicine projects by aggregating genetic and genomic data from labs and clinical data from electronic health records and helping bring it into clinician workflows helping with faster diagnosis of for heritable conditions, and more efficient targeting of personalized treatment plans.

Its addition to the AccessDX portfolio which includes the MedTek21 platform for diagnostic-based CDS will help provider and other customers as they establish, build and advance precision medicine programs.

THE LARGER TRENDClinical integration of genetics and genomics is advancing across an array of specialties not just oncology and cardiology but neonatology, pediatrics and behavioral health. But easy access to that data within the EHR is essential to gaining clinician buy-in and enabling precision insights for improved patient outcomes.

Still many smaller providers think precision medicine is beyond their means. That's not true, however. In interviews with Healthcare IT News, 2bPrecise co-founder and Chief Medical Officer Dr. Joel Diamond has said that pharmacogenomics is one logical entry point.

At HIMSS21 earlier this month, UPMC CMIO Dr. Robert Bart said he shared that sentiment.

"In the pharmacogenomics space, there's opportunity for all levels of healthcare systems to be involved," he said predicting that that precision med discipline would soon "filter down and become the standard of care."

He added: "One of the reasons I'm so high on pharmacogenomics is that there can be a big benefit on medication adherence.

"There's a nice opportunity where the payers are aligned, because they feel there's financial benefit in healthcare. The clinical side is aligned, because they feel that they can get better therapy and therapeutic treatment for the patient. And the patients are aligned because they want the right medication at the right dose for them personally."

ON THE RECORD"We're thrilled to welcome the 2bPrecise team and platform as we execute on our combined vision for democratizing the use, interpretation and delivery of advanced diagnostic solutions at the point of care," said Joe Spinelli, SVP of Product & Strategy for AccessDX. "Combined, our worldwide organization will be able to accelerate the pace of innovation and best serve the needs of healthcare organizations that continue to expand their adoption of actionable precision medicine solutions."

"AccessDX is a genuine leader in genomic information management. Our collective capabilities will serve as a force multiplier for the practical utilization of precision medicine," said Assaf Halevy, founder and CEO of 2bPrecise. "With a unified mission to drive dimensional change in healthcare, the combined talents and energy of 2bPrecise and AccessDX will compound acceleration in delivering on our vision of intelligent, personalized care for the good of healthcare organizations and the patients they serve."

Twitter:@MikeMiliardHITNEmail the writer:mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.

More here:
2bPrecise acquired from Allscripts by AccessDX - Healthcare IT News

Elite Testing and Wellness Launches Innovative DNA Testing and IV Therapy in the Atlanta Market – PRNewswire

Posted on by

ATLANTA, Dec. 16, 2020 /PRNewswire/ -- Elite Testing and Wellness at the Chastain Surgery Center is excited to announce the launch of innovative genetic testing and IV drip therapy services in the Atlanta market. The DNA tests are the future of health optimization and include a DNA fitness test, micronutrient test, pharmacogenomics test, and a food sensitivity test. Alongside the launch of genomic testing products, Elite is launching a full suite of IV therapy products. The IV Drips available at Elite will include a Beauty Drip, Immunity Drip, Hangover Drip, All-In-One Drip, Meyer's Cocktail Drip, and a Pre & Post Surgery Drip. Elite will also offer Custom IV Drips based on your micronutrient analysis to address vitamin and mineral deficiencies.

"We are excited about the launch of all the new products and services at Elite," says Managing Director of Elite Testing and Wellness, Courtney Rodriguez. "We started this business earlier in 2020 to help address the need for reliable, fast COVID-19 testing. As more providers have entered the area, we are transitioning the company to focus on the next generation of health optimization. We believe these new products and services are going to allow the people of Atlanta to take control of their health with some of the most innovative technology and approaches used around the world."

Elite Testing and Wellness is a new DNA testing center & IV Drip Therapy lounge in Atlanta. The DNA testing products and IV Therapy services work together to create a holistic approach to the future of health. With DNA testing, Elite helps patients gain access to important genetic data analysis on the impact of fitness, diet, pharmaceuticals, and more on their health. Elite works with patients to develop a fitness plan, diet plan, and IV therapy plan for optimal health & performance based on the patient's genetics.

Dr. Alan N. Larsen, Medical Director of Elite Testing and Wellness, had this to say, "We are proud to add Elite Testing & Wellness to the Alan N. Larsen Family of Brands alongside Buckhead Plastic Surgery, LUX Med Spa, and Chastain Surgery Center. The launch of these innovative products & services gives Atlanta a luxurious location for the future of health optimization."

To learn more about DNA Testing & IV Therapy, contact Elite Testing and Wellness at 404.689.6860

SOURCE Elite Testing and Wellness

Continued here:
Elite Testing and Wellness Launches Innovative DNA Testing and IV Therapy in the Atlanta Market - PRNewswire

Moving Genomics to the Clinic – World Economic Forum

Posted on by

Context

The promise of precision medicine hinges on our ability to use highly personal data about individuals and populations to prevent, screen, diagnose or treat patients with disease.

Healthcare providers are increasingly using genetic information as a routine part of prenatal, pediatric and cardiovascular care. The use of genetic information is even more common in the areas of rare disease, oncology and pharmacogenomics (looking at how genes affect a person's response to drugs).

Beyond these more specialized disciplines, population screening for actionable hereditary health risks is of interest to many healthcare organizations. The explosion in popularity of direct to consumer genetic testing is allowing many members of the public to learn more about their predisposition to certain health conditions like cancer and heart disease. Patients and the general public want to consider this information in health and healthcare decisions, and researchers, along with innovators in the genetic testing and support services industry, are increasingly advocating for its inclusion in clinical practice.

Many experts and innovators argue that genetic testing should become a routine part of clinical care as a means to identify and treat diseases. It would enable a more proactive approach to identifying risks and establishing management strategies for a population-wide precision medicine experience.

Most healthcare organizations and physicians are not incorporating these tests into routine practice. After an extensive scoping exercise, the Forums precision medicine team found that the most significant barrier to moving genetic testing into clinical practice for broader populations is the lack of coverage for genomic testing i.e., that a physician or healthcare institution will not be reimbursed for the process of ordering and returning the results of a test.

While this is an over simplification of the complexity of the situation, there is general discomfort that the science on which many of todays genetic and genomic tests are based is still evolving, and thus many physicians and payers are unsure of the utility of genetic testing to drive clinical care decisions in the large, diverse populations they serve.

We plan to explore, design and test incentives to accelerate building the evidence base for clinical efficacy and utility as a way to increase coverage of genetic testing and screening. Increasing the evidence base serves two purposes: to improve physician comfort with the clinical utility of such tests and to demonstrate to payers that tests do elicit action for the populations that they cover. Increasing the incentives for payers to cover genetic tests would allow clinicians and patients to significantly contribute to building the evidence base for the utility of genetic tests in real world settings. This in turn enables population-wide genetic testing that, over time, will drive our ability to personalize the way we treat, mitigate or manage health risks to patient populations. This project will involve several steps:

- Validate key barriers to genetic screening and testing, considering different models of healthcare delivery, cultural and ethical expectations, and stages of healthcare-system development

- Determine which genetic testing use case(s) can be the focus of stakeholder dialogues and activities

- Create original, new analysis of the economic value of genetic testing across four use cases: cancer testing, rare disease testing, population health testing, and carrier testing

- Identify, design and pressure test incentives to address the gaps leading to low or inconsistent levels of coverage

Impact

The project will address a foundational element of precision medicine: our ability to effectively deploy genetic screening and testing into routine clinical care. To do so, healthcare providers must be confident that genetic screening tests provide them with value and with actionable results for the populations which they serve. Payers need to know that tests are clinically actionable, and lead to improved outcomes for patients. This project will focus on the value of genetic testing and incentives to generate sufficient proof of the utility genetic testing for healthcare providers and the payer community globally.

Read more from the original source:
Moving Genomics to the Clinic - World Economic Forum

Global Genomic Medicine Market Analysis With Key Players, Applications, Trends And Forecasts 2028 – KSU | The Sentinel Newspaper

Posted on by

DBMR has added a new report titled Global Genomic Medicine Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The Global Genomic Medicine Market research report offers the market insights from the statistics, gathered from the reliable market information such as manufacturers, channel partners, decision-makers and regulatory bodies. It outlines segment of the market investigates progression such as drivers, limitations and opportunities that at present strongly affect the market and could impact the market in future, Market share analysis mentioned in this report with a specific end goal to clarify the intensity of rivalry between driving market players working over the globe. It validated primary and secondary research methodology and data sources that are implied to collect key information like market size, trends, revenue and analysis.

The main objective of this Global Genomic Medicine Market report is to analyze the opportunities, threats and market drivers. Key insights like competitive industry scenario, gross margin analysis, price structure and cost analysis. It correctly calculates the global market share of important sections, regions and businesses. This research report examines the international market on the business plan based on numerous business verticals.

Genomicmedicinemarket is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to grow at a CAGR of 9.70% in the above-mentioned forecast period. Increasing scientific research on genomic medicine is expected to create new opportunity for the market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-genomic-medicine-market&pm

Genomic medicine is that part of the science which uses genomic information for the study of our DNA and their interactions with the health. They have the ability get the details about the typical biological information of an individual and use them to offer effective treatment.

Rising government investment in theprecision medicineis expected to drive the market growth. Some of the other factors such as increasing application area of genome, increasing number of genomics project and increasing usage for advanced sequencing in cancer pharmacogenomics & rare disorder diagnosis which will further accelerate the genomic medicine market in the forecast period of 2020 to 2027.

Dearth of awareness among healthcare providers, volatility in the regulation scenario and lack of adoption of genomic medicine will hamper the market growth.

Competitive Landscape and Genomic Medicine Market Share Analysis

Genomic medicine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to genomic medicine market.

The major players covered in the genomic medicine market report are BioMed Central Ltd, Cleveland Clinic., Genome Medical, Inc., Aevi Genomic Medicine, Inc., DEEP GENOMICS, Congenica Ltd., Editas Medicine, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Genomic Medicine Market Scope and Market Size

Genomic medicine market is segmented of the basis of application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-genomic-medicine-market&pm

Genomic Medicine Market Country Level Analysis

Genomic medicine market is analysed and market size insights and trends are provided by application and end user as referenced above.

The countries covered in the genomic medicine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genomic medicine market in the forecast period of 2020 to 2027. This is due to increasing R&D in the genomic medicine and availability of various universities offering education programs on genomic medicine.

The country section of the genomic medicine market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Genomic medicine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for genomic medicine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the genomic medicine market. The data is available for historic period 2010 to 2018.

Customization Available: Global Genomic Medicine Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Genomic Medicine Market Analysis With Key Players, Applications, Trends And Forecasts 2028 - KSU | The Sentinel Newspaper

Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo Dose – DocWire News

Posted on by

This article was originally published here

OMICS. 2020 Dec 10. doi: 10.1089/omi.2020.0208. Online ahead of print.

ABSTRACT

Pharmacogenomics, nutrigenomics, vaccinomics, and the nascent field of plant omics are examples of variability science. They are embedded within an overarching framework of personalized medicine. Across these public health specialties, the significance and biology of the placebo response have been historically neglected. A placebo is any substance such as a sugar pill administered in the guise of medication, but one that does not have pharmacological activity. Placebos do have clinical effects, however, that can be substantive in magnitude and vary markedly from person-to-person depending, for example, on the type of disease, symptoms, or clinical trial design. Research over the past several decades attests to a genuine neurobiological basis for placebo effects. All drugs have placebo components that contribute to their overall treatment effect. Placebos are used in clinical trials as control groups to ascertain the net pharmacological effect of a drug candidate. Not only less well known but also relevant to rational therapeutics and personalized medicine is the nocebo. A nocebo effect occurs when an inert substance is administered in a context that induces negative expectations, worsening patients symptoms. With the COVID-19 pandemic, there are high public expectations for new vaccines and medicines to end the contagion, while at the same time antiscience, post-truth, and antivaccine movements are worrisomely on the rise. These social movements, changes in public health cultures, and conditioned behavioral responses can trigger both placebo and nocebo effects. Hence, in clinical trials, forecasting and explaining placebo and nocebo variability are more important than ever for robust science and personalized health care. Against this overarching context, this article provides (1) a brief history of placebo and (2) a discussion on biology, mechanisms, and variability of placebo effects, and (3) discusses three emerging new concepts: placebogenomics, nocebogenomics, and augmented placebo, that is, the notion of a placebo dose. We conclude with a roadmap for placebogenomics, its synergies with the nascent field of social pharmacology, and the ways in which a new taxonomy of drug and placebo variability can be anticipated in the next decade.

PMID:33305994 | DOI:10.1089/omi.2020.0208

Link:
Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo Dose - DocWire News

Global Pharmacogenomics Market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -…

Posted on by

Global Pharmacogenomics Market Industry Trends and Forecast to 2027 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. To build an influential report, detailed market analysis has been conducted with the inputs from industry experts. By working on a number of steps for collecting and analysing market data, this supreme market research report is prepared with the expert team. It describes various definitions and segmentation or classifications of the industry, applications of the industry and value chain structure. Businesses can obtain a complete knowhow of general market conditions and tendencies with the information and data involved in the credible Global Pharmacogenomics Market business report. The foremost areas of market analysis such as market definition, market segmentation, competitive analysis and research methodology are looked upon very vigilantly and precisely throughout the report.

Global pharmacogenomics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenomics-market&pm

Competitive Landscape and Global Pharmacogenomics Market Share Analysis

Pharmacogenomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global pharmacogenomics market.

The major players covered in the global pharmacogenomics market are Abbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, OPKO Health, Inc, Teva Pharmaceutical Industries Ltd, Myriad Genetics, Inc., QIAGEN,OneOme, LLC, Illumina, Inc, Empire Genomics, LLC, and Dynamic DNA Laboratories among others.

The factors primarily driven the growth of pharmacogenomics market are high adoption of personalized therapy. In addition, high prevalence of life-threatening disorders globally and improvement in molecular techniques for developing pharmacogenomics-based therapeutics are some of the impacting factors for the growth of this market. Nevertheless, less trained expertise or technically skilled professionals and coupled with difficulties in terracing gene variation that significantly affects the drug response are the factors that hinder the growth of this market.

Pharmacogenomics is the study of how human genes affect the way bodies responds to the medications. It is emerging field which combines the pharmacology and genomics to develop highly effective and right or safe medicines tailored to the patients genetic makeup.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharmacogenomics-market&pm

Global Pharmacogenomics Market Scope and Market Size

Pharmacogenomics market is segmented on the basis of technology, application, end-users and distribution channel.

Table of Contents-Snapshot

Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenomics-market&pm

Pharmacogenomics Market Country Level Analysis

Pharmacogenomics market is analysed and market size information is provided by country, technology, application, end-users and distribution channel as referenced above.

The countries covered in the global pharmacogenomics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth throughout the forecasted period due to the presence of refined healthcare expenditure and increased patient awareness level as well as preference personalized medicines. Europe is considered a second largest growing regional segment owing to the growing geriatric population and rising prevalence of chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pharmacogenomics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

The rest is here:
Global Pharmacogenomics Market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -...

Pharmacogenomics Market Report 2019 to register a CAGR of 10.8% to reach US$ 20.83 Billion by 2026 | – PharmiWeb.com

Posted on by

Global Pharmacogenomics Market Insights

Pharmacogenomics is the study of how genes affect an individuals response to drugs. This is done by correlating gene expression changes and Single-Nucleotide Polymorphisms (SNPs) with a drugs efficacy or toxicity. It is relatively a new field that combines genomics and pharmacology to develop efficient and safe medications that will customized to an individuals makeup. Growing concerns for the early identification of drug advertises, drug safety, and growing need for timely compliance to regulatory guidelines have led the introduction of new technologies and methods by pharmaceutical manufacturers and other intermediaries. These advancements are expected to fuel adoption of pharmacogenomics technology during the forecast period. Pharmacogenomics has different restorative applications such as cardiology, oncology, neurological disorder, and pain management. In this manner, through further headways in this field, by enhancing drug safety, optimizing drug therapy with increasing patient compliance and further reducing healthcare costs is expected to result in the meteoric growth of the pharmacogenomics market over the forecast period.

Various government agencies are taking proactive initiatives to implement pharmacogenomics in drug development and surveillance, so that patients can benefit from advances in genomic science and technology. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications. For instance, in 2017, Armonica Technologies, Inc., a U.S.-based company received US$ 1.5 Mn from the states US$ 40 Mn catalyst fund. This fund is intended for seed early stage-companies in New Mexico that are involved in developing novel technologies. Clinically personalized medicine is also expected to provide tools that will enhance the traditional approaches for estimating the risk/benefit of an intervention in patients.

The global pharmacogenomics market was valued at US$8,357.3million in 2017 and is expected to witness a CAGR of10.8%during the forecast period (2018 2026).

Figure 1. Global Pharmacogenomics Market Share, by Technology Type (%)

Market Dynamics- Drivers

Increasing demand for various techniques to pinpointing diagnoses down to the subtype of chronic conditions will drive the pharmacogenomics market

Growing research and development activities related to sequencing and especially generation sequencing is expected to boost the demand for pharmacogenomics tests, which in turn, is expected to drive the global pharmacogenomics market growth during the forecast period. Moreover, significant progress in the aspects of NGS technology, platform, and data analysis solutions is propelling widespread, as it shows validresults for problematic areas that have long plagued the drug development industry.

Furthermore, growing prevalence of several infectious and non-infectious diseases is expected to propel the global pharmacogenomics market over the forecast period, as it is boosting the demand for regulated next-generation sequencing-based clinical trial assays and companion diagnostics. According to U.S. Food and Drug Administration (FDA) statistics, over 100,000 people in the U.S. die each year from injurious responses to drugs that were correctly prescribed by a physician. Additionally, over 2.2 million people endure acute, though not fatal, side effects. Worldwide, BioWorld estimates those figures increase to 200,000 deaths and over 4.5 million people suffering serious side effects.

Pharmacogenomics tests are expected to predict susceptibility to maladies as well as create therapeutics tailored to an individuals specific genetic profile. This in turn, is expected to increase market growth.

Introduction of novel technology leading to new product launch is a prominent factor fueling market growth

Today, screening of known polymorphic drug metabolism enzymes and transporters (DMET) is rapidly becoming routine practice in clinical research. So manufacturers are currently focusing on various approaches to pharmacogenomics analysis to provide rapid and cost-effective solutions for both the screening of known polymorphisms and discovery of novel variants. Few of the advanced technologies already been commercialized like Illumina HiSeq-2000 and HiScan, Roche 454 GSFLX Titanium and the Applied Biosystems SOLiD Analyzer 5500xl. Besides, the combination of goldstandard Applied Biosystems TaqMan Assays with the high-throughput Applied Biosystems Open Array manufactured by Thermo Fisher Scientific Inc., enables analysis of common variants, typically in under four hours with the flexibility to modify array content.

Market Dynamics- Restraints

Lack of proper diagnostic testing due to lack of trained personnel, high costs associated with tests, dearth of laboratory facility, and lack of standardization and validation of the test procedures are expected to restrain the global pharmacogenomics market growth in the near future.

Figure 2. Global Pharmacogenomics Market Share, by Region (%)

Regional Insights

Among regions, North America accounted for the largest market share and is witnessed fastest growth, owing to presence of major key players and strategic collaborations among them. Asia Pacific is expected to register significant growth rate after North America, owing to increased investments in R&D and increasing number of clinical trials. In November 2016, according to the Pharmaceutical Research and Manufacturers of America (PhRMA) data, EFPIA and PhRMA member companies conducted 825 clinical trials for various therapeutic indications across Japan in 2015, showing an increase of 21% in comparison to 2013. Furthermore, Latin America and Africa are expected to exhibit moderate growth rate, as countries in these regions have shown considerable interest in research andcontinuous efforts made by major players to expand their business in these regions. South African Medical Research Council (SAMRC) has collaborated with Beijing Genomics Institute in April 2017, to understand the genetic composition of the population, which is expected to augment growth of the pharmacogenomics in South Africa.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/pharmacogenomics-market-to-surge-past-us-2083-billion-by-2026-468

Competitive Landscape

Key companies in the market are involved in various growth strategies such as collaboration and agreement, in order to gain competitive edge in the market. Objective of these collaborations between the organization and the companies is identification of specific tumor targets by expansion of known mutations associated with defective DNA repair. Companies are engaged in development of single comprehensive tests that can capture a large. amount of relevant content. For instance, in 2017, Qiagen N.V. and Bristol-Myers Squibb signed an agreement for use of Next Generation Sequencing technology to develop gene expression profiles for immuno-oncology therapies.

Major companies operating in the global pharmacogenomics market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl, and Assurex Health Inc.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

View post:
Pharmacogenomics Market Report 2019 to register a CAGR of 10.8% to reach US$ 20.83 Billion by 2026 | - PharmiWeb.com

Global Protein Detection And Quantitation Market To Reach A New Threshold of Growth By 2026 – The Courier

Posted on by

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute Protein Detection And Quantitation market report based on the growth and the development of theProtein Detection And Quantitation marketis systematically listed down. The Protein Detection And Quantitation market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific Protein Detection And Quantitation market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The Protein Detection And Quantitation market report has the dominant market players Promega, Genecopoeia, Garland Science, Labome, Thermo Fisher Scientific explained in detail.

Sample of global Protein Detection And Quantitation Market Report at::https://www.marketresearchstore.com/report/global-protein-detection-and-quantitation-market-report-2020-752127#RequestSample

The essential futuristic segments such as {Bradford, Coomassie, BCA}; {Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology, Breeding and Animal Livestock} have also been detailed out in the Protein Detection And Quantitation market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the Protein Detection And Quantitation market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global Protein Detection And Quantitation market

Theoretical analysis of the global Protein Detection And Quantitation market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The Protein Detection And Quantitation market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the Protein Detection And Quantitation market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire Protein Detection And Quantitation market from in and out. The most eye-catching format of the Protein Detection And Quantitation market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-protein-detection-and-quantitation-market-report-2020-752127

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global Protein Detection And Quantitation market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the Protein Detection And Quantitation market?4. What are the key outcomes of the Protein Detection And Quantitation market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

The Protein Detection And Quantitation market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global Protein Detection And Quantitation Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:https://www.marketresearchstore.com/report/global-protein-detection-and-quantitation-market-report-2020-752127#InquiryForBuying

Originally posted here:
Global Protein Detection And Quantitation Market To Reach A New Threshold of Growth By 2026 - The Courier

Patients and carers views must be involved in the rollout of precision medicine – The BMJ – The BMJ

Posted on by

The sequencing of the human genome has begun to enhance our understanding of the biological mechanisms underlying chronic diseases, for example asthma. The twentieth century model of asthma management is often that of a generic disease with grades of severity, treated by adding layer on layer of medicine. However, the discoveries that follow from the description of the human genome are influencing our thinking. They are enriching the established milieu with additional information about new individual pathways, urging us to move from mostly one-size-fits-all treatment to genuinely personalized care. [1] We may soon have the power to decide whether or not we can let this novel information fine-tune the management of chronic diseases in wider populations.

Or will we?

We are only empowered by information when we understand and realise it. Currently, there exists a gap between the information about genomics and chronic diseases that researchers know and share through articles in specialist journals, and the understanding of this information among patients and carers, the public, and many healthcare professionals. Unless this gap closes, doctors, nurses, patients and the public cannot make the right decisions about future patient care, and a small body of experts, with or without links to industry, may remain in the driving seat through sheer knowledge power, and this might not work in the best interests of the patients.

A recent systematic review of 21 studies demonstrates an overall interest in 9000 members of the public, including patients, almost exclusively from North America and Europe, to engage in a wider discussion on personalised medicine. [2] However, other than one study from Singapore, we could identify no evidence of a systematic exploration of the publics views on personalised medicine from Africa, South America and Asia, where over half the worlds populations live, and where personalised medicine-related treatment approaches will inevitably influence the management of common diseases over the next decade.

Historically, doctors may not have been efficient at seeking patients views about new treatment choices, but views are shifting in the North, and we were pleased to note the breadth of studies seeking the views of the public regarding personalised medicine. Many of us in the developed world are actively seeking patient feedback regarding our day-to-day performance, while researchers are exploring opportunities for public engagement to discuss future medicine and inviting public involvement to strengthen clinical trial design.

How much of this is happening outside the developed world? The treatment choices are creeping in, often at different rates, depending on ability to pay. From the patients point of view, there is arguably an even greater need to think about cost versus benefit. Our exploratory discussions last year with rural and urban populations in India revealed one clear message: people, particularly the young, are keen to engage in this process, but there is very little scope for discussion. Young women employed in rice fields spared their valuable morning time learning how a skin barrier defect might worsen their childs asthma or eczema and joined in the discussion on how this could be prevented through the use of emollients that are available in the local market. [3,4] Speaking in the local language (Bengali) and translating from English as necessary, we used models and pictures, communicating allergy advice. As doctors and researchers, we learnt that there are fewer cultural, educational and economic barriers to worldwide public participation in discussing the pros and cons of medical treatments than we currently perceive.

We know that the price of ignoring the views of patients and carers is high. We run the risk of mis-diagnosis, overdiagnosis and overtreatment, or in ignoring the publics views when developing research programmes. In Europe, a clear and articulate patient voice is guiding the development of these interventions. There are, however, major healthcare and societal costs if patients and carers are not involved worldwide in the roll out of personalised medicine over the forthcoming years.

Somnath Mukhopadhyay is Chair of Paediatrics at the Royal Alexandra Childrens Hospital and the Brighton and Sussex Medical School, UK. He is a consultant in childrens respiratory diseases and allergy

Katy Fidler is Clinical Senior Lecturer in Paediatrics at the Royal Alexandra Childrens Hospital and Brighton and Sussex Medical School, UK. She is a consultant in childrens infectious diseases.

Ciara Holden is a clinical academic fellow and specialist registrar in paediatrics at the Royal Alexandra Childrens Hospital in Brighton, UK

Christina Jones is a senior lecturer in Clinical Psychology at the University of Surrey, UK.

All the members of this group have a strong interest in the development of new personalised / precision medicine-linked treatment strategies for childrens allergy and asthma and other chronic diseases, with the aim of improving quality-of-life and reducing disease morbidity, and are currently performing exploratory research or randomised controlled trials to develop these strategies.

Competing interests: None declared

Read the original:
Patients and carers views must be involved in the rollout of precision medicine - The BMJ - The BMJ

Product Portfolio Analysis and Technological Development of Pharmacogenomics Market during the forecasted period – TechnoWeekly

Posted on by

The Pharmacogenomics Market research report recently presentedby Prophecy Market Insights which provides reliable and sincere insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the Pharmacogenomics market over the forecast period (2019-2029).

Influences of the market report:

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Pharmacogenomics market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

Segmentation Overview:

The Pharmacogenomics research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Pharmacogenomics market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Highlights of the Report

Complete access to COVID-19 Impact on the Pharmacogenomics market dynamics, key regions, market size, growth rate and forecast to 2029

The report on the Pharmacogenomics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Some important Questions Answered in Pharmacogenomics Market Report are:

PharmacogenomicsMarket by Top Manufacturers:

Thermo Fisher Scientific Inc., Qiagen N.V., F.Hoffmann-La Roche AG, Abbot Laboratories, Diatech Pharmacogenetics, and Assurex Health Inc.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the rest here:
Product Portfolio Analysis and Technological Development of Pharmacogenomics Market during the forecasted period - TechnoWeekly

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX – BioSpace

Posted on by

MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the Company), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (Agreement).

Key Highlights

The Agreement will support GTG to expand its product offering and establish the mental health vertical by harnessing PREDICTIX, Taliazs pioneering decision-support and management platform to optimize patient treatment for mental health disorders. Starting in the field of depression, this genomic-based, Artificial Intelligence (AI) driven antidepressant selection technology, marks GTGs first foray into pharmacogenomics1.

George Muchnicki, GTGs Interim CEO stated: We are incredibly pleased to have partnered with Taliaz to bring their predictive and personalized mental health product to Australia and New Zealand. GTG are at the forefront of providing personalized and predictive products to empower patients to make informed decisions about their health. This distribution agreement is our first external product partnership and our first product within the mental health vertical. Mental health has remained at the forefront of media discussions and government initiatives within Australia, New Zealand and globally due to the ongoing social and economic impact and given the impact from the current global pandemic. We look forward to working closely with the Taliaz team to deliver their product into these markets at this critical time.

The execution of the Agreement is reliant on product regulatory clearance by the Therapeutic Goods Administration (TGA) in Australia and Food and Drug Administration (FDA) in the USA. Once cleared, GTG has committed to providing a minimum distribution of 8,000 tests over the initial three-year term with an associated minimum cost to GTG of $200,000 over the term, inclusive of licencing fees and a percentage based fee per test paid to Taliaz. Subject to the regulatory clearance process, GTG anticipates that PREDICTIX will be made available for sale and distribution in Australia and New Zealand in Q3 FY21 on GTGs existing Consumer Initiated Testing (CIT) platform, with end-customer pricing to be determined but anticipated to be in line with existing GTG product pricing.

PREDICTIX, developed by the private Israeli company, Taliaz, addresses the growing burden on society from depression, with 1 in 10 Americans2 and 1 in 8 Australians3 prescribed antidepressants per year. PREDICTIX enables a more accurate and rapid treatment plan for patients suffering from depression, reducingtreatment costs and the overall associated economic burden.

PREDICTIX is an algorithmic-based decision support tool that can improve todays antidepressant prescribing accuracy by 47%4. Combining DNA testing with AI, PREDICTIX empowers doctors to improve the assessment, treatment, and management of mental health disorders.

The PREDICTIX technology uses AI to analyse multiple data streams, including patients genomic, clinical history and demographic background, providing doctors with a personalized patient report. The report ranks the statistical efficacy and potential side effects of various antidepressant medication based on each patients genetic makeup andhealth record. This helps doctors optimize prescribing decisions for patients diagnosed with depressive disorder, where there is currently a long and painful trial and error period. PREDICTIX is CE-registered and commercially available in the UK, France and Israel, with the process underway for TGA approval.

Dekel Taliaz, CEO and Co-founder of Taliaz said, We are excited to partner with Genetic Technologies, world-leaders in the genetic risk assessment space. This new partnership will support rapid commercialization of PREDICTIX to help more depression sufferers in Australia, New Zealand and the USA, while adding a complementary and advanced mental health solution to GTGs growing suite of DNA tests.

The Agreement strengthens GTGs mission in creating a suite of tests to enable a holistic and predictive health assessment for patients, which can be adjusted to address the individual patient risks and needs. Establishing the first product within the mental health and pharmacogenetic space continues GTGs progress towards being able to offer a highly comprehensive suite of polygenic risk assessment tests via GTGs CIT platform and additional sales and marketing avenues as these are progressed.

This announcement was approved by the Board of Directors of Genetic Technologies Limited.

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Companys lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit http://www.gtglabs.com

About Taliaz

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE-registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence, PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. Starting in the field of depression, the PREDICTIX Genetics and PREDICTIX Digital products can improve todays prescribing accuracy by up to 47%4.

For more information, please visit predictix.ai.

Originally posted here:
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX - BioSpace

The Genomic Medicine market to go the reverse transversal way in the next decade – The Think Curiouser

Posted on by

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/11323

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are BioMed Central Ltd., Cleveland Clinic, The University of Texas MD Anderson Cancer Center, The Manchester Centre for Genomic Medicine, Center for Genomic Medicine to name a few. The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

You Can Request for TOC[emailprotected]

https://www.persistencemarketresearch.com/toc/11323

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
The Genomic Medicine market to go the reverse transversal way in the next decade - The Think Curiouser

Direct-to-Consumer Genetic Testing: Global Markets and Technologies – GlobeNewswire

Posted on by

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" - https://www.reportlinker.com/p05987656/?utm_source=GNW

This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR) and genotyping microarrays.

The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics and PCR.

The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); by technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).

The ancestry market segment is analyzed by technology and by ethnicity (African, Asian, European, Latino, other). The health market segment is analyzed by technology and by disease category (cancer, cardiovascular, complex common, pharmacogenomics, rare diseases and other). The lifestyle market segment is analyzed by technology and by application (genetic relatedness, nutrigenomics, personal traits, weight management/fitness, other)

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

More than 55 companies in the DTC genetic testing industry are profiled in this report.

The analyst provides a summary of the main industry acquisitions and strategic alliances from January 2019 through September 2020, including key alliance trends.

Report Inludes: - 12 data tables and 39 additional tables - An overview of the global markets and technologies for direct to consumer (DTC) genetic testing - Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025 - Information on key genomic regions associated with genetic testing and description of instruments and technologies used for DTC genetic testing - Coverage of DNA sequencing; microarray; and software industries and description of the key initiatives in the genetic testing industry - Detailed analysis of the current market trends, market forecast and discussion of technological, regulatory and competitive elements as well as economic trends affecting the future marketplace for direct to consumer (DTC) genetic testing and impact analysis of COVID-19 on the market - Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry - Profiles of the key companies in the DTC testing industry, including Chendu 23Mofang Biotechnology Co. Ltd (23Mofand), Genetic Technologies Ltd, Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc.

Summary: Direct-to-consumer (DTC) genetic testing involves the analysis and interpretation of a persons genome. A consumer can access DTC genetic testing from a commercial company or from a health care provider.

DTC genetic testing has evolved in the past 10 years. Initially it focused on personal applications outside traditional health care, such as exploring ancestry and has trended toward interfacing with clinical care in non-traditional ways, such as partnerships between DTC companies with health systems.

Analysis of a customers genome helps to know about their ancestry inference, disease risks and other personal traits. Based on this, the main applications include ancestry, health and lifestyle.

Several factors are driving growth in the DTC genetic testing industry, including a shifting emphasis on health-related applications, the rise of personalized genomics and increasing convenience of ordering goods and services from virtual at-home settings. This latter trend has been accelerated by the COVID- 19 pandemic.

There is rising public awareness of DNA and its impact on health and genetic disorders, ancestry and lifestyle. These trends are having a favorable impact on the at-home genetic testing market. This report provides an in-depth analysis of the DTC genetic testing industryRead the full report: https://www.reportlinker.com/p05987656/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the rest here:
Direct-to-Consumer Genetic Testing: Global Markets and Technologies - GlobeNewswire